logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Fuyao Glass Industry Group (03606) will distribute an interim dividend of 1 yuan per share on November 6.

date
17:13 18/08/2026
avatar
GMT Eight
Fuyao Glass (03606) announced that the company will distribute an interim dividend of 1 yuan per share on November 6, 2026.
Fuyao Glass Industry Group (03606) announced that the company will distribute an interim dividend of 1 yuan per share on November 6, 2026.
Related Articles
China Stock
Hengyu Technology (688309.SH): The preliminary transfer price for the inquiry has been determined to be 67.81 yuan per share.
HK Stock
ALPHAMAB-B(09966): The new drug application for Anritanib (KN026) as a first-line treatment for HER2-positive advanced breast cancer has been accepted by the National Medical Products Administration.
HK Stock
ZHihu-W (02390) spent $126,800 to repurchase 119,600 shares on August 17.
Hengyu Technology (688309.SH): The preliminary transfer price for the inquiry has been determined to be 67.81 yuan per share.
China Stock
ALPHAMAB-B(09966): The new drug application for Anritanib (KN026) as a first-line treatment for HER2-positive advanced breast cancer has been accepted by the National Medical Products Administration.
HK Stock
ZHihu-W (02390) spent $126,800 to repurchase 119,600 shares on August 17.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.